Semaglutide Market Faces Slump as Excess Inventory Hits ₹100 Crore

The much-anticipated boom in the Indian semaglutide therapy market has encountered a significant reality check following a period of hyper-growth. After an initial surge driven by the entry of affordable generics, the sector is now grappling with a massive inventory overhang that threatens to impact margins for pharmaceutical players.

From Hyper-Growth to Sudden Slowdown

The obesity and diabetes therapy market, currently valued at approximately ₹2,000 crore, experienced a dramatic shift in momentum between April and May. In April, the market saw explosive month-on-month (m-o-m) growth, with value surging by 50% and volumes jumping by 88%. This frenzy was largely fueled by the patent expiry of semaglutide on March 20, which allowed major Indian pharmaceutical players like Sun Pharma, Dr. Reddy’s, and Torrent to flood the market with cheaper generic versions.

However, the May data tells a different story. According to Pharmarack, the value growth slowed down to a mere 6% m-o-m, while unit growth settled at 12%. This deceleration has left the supply chain in a precarious position.

The ₹100 Crore Inventory Overhang

The sudden cooling of demand has created a massive buildup of unsold stock across the distribution network. Industry sources and the All India Organisation of Chemists and Druggists (AIOCD) estimate that the excess stock held in the trade channel is worth nearly ₹100 crore.

Currently, stockists and wholesalers are holding between 50 to 60 days of inventory, significantly higher than the industry standard of 30 to 45 days. In response to this glut, channel partners have reportedly frozen fresh procurement from pharmaceutical manufacturers, opting instead to liquidate existing stocks before placing new orders. Rajiv Singhal, General Secretary of AIOCD, confirmed that this inventory overhang is a direct result of May's slower-than-anticipated sales.

Regulatory Hurdles and Market Drivers

Industry experts suggest that the moderation in sales may not just be a matter of supply-demand mismatch but could also be linked to tighter regulatory oversight. Following government advisories and new prescribing restrictions announced in April, GLP-1 therapies are now mandated to be prescribed only by qualified specialists. This move is intended to ensure clinical safety but has likely added friction to the prescribing process.

Despite the semaglutide slowdown, other segments of the GLP-1 receptor agonist market remain resilient. Mounjaro (tirzepatide), marketed by Eli Lilly, remains the largest selling therapy in this category, with its May sales rising by 12% to reach ₹136 crore. This performance contributed to the broader growth of India's ₹2.5 lakh crore organized pharma retail market, which grew by 11% in May, bolstered largely by chronic therapies.

Key Takeaways

  • Inventory Glut: The semaglutide trade channel is currently saddled with approximately ₹100 crore in excess stock, with wholesalers holding up to 60 days of inventory.
  • Growth Deceleration: After a massive 50% value surge in April, semaglutide market growth slowed to just 6% in May.
  • Regulatory Impact: New guidelines requiring specialized doctors to prescribe GLP-1 therapies are believed to be a contributing factor to the recent sales moderation.